Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor. 1998

S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
Research Department, Novartis Pharmaceuticals Corporation, Summit, NJ 07901, USA.

Optimization of an aminophosphonic acid series of compounds for inhibition of endothelin-converting enzyme (ECE) has led to the discovery of CGS 31447. This compound reversibly inhibited the activity of recombinant human ECE-1 with an IC50 value of 21 nM. The effect of CGS 31447 was not due to nonspecific chelation of the zinc ion at the catalytic center of ECE-1 by the phosphonic acid of the inhibitor. Determination of kinetic parameters of ECE-1 in the presence of 5-15 nM CGS 31447 revealed the competitive nature of the compound; a K1 of 7 nM was obtained. CGS 31447 infused at concentrations of 0.01, 0.1, and 1.0 microM inhibited the mean increase in big ET-1-induced pressor responses in isolated and perfused rat kidneys by 7, 39, and 68%, respectively, compared with the controls. These results demonstrate that CGS 31447 is a potent, reversible, and competitive inhibitor of ECE-1.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011498 Protein Precursors Precursors, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic

Related Publications

S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
November 2000, Journal of cardiovascular pharmacology,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
September 2000, Japanese journal of pharmacology,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
November 2000, Journal of cardiovascular pharmacology,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
January 2005, Cardiovascular drug reviews,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
January 1984, European journal of clinical pharmacology,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
January 2000, Life sciences,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
August 2002, Clinical science (London, England : 1979),
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
May 2002, Canadian journal of physiology and pharmacology,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
January 1995, Journal of cardiovascular pharmacology,
S S Shetty, and P Savage, and D DelGrande, and S De Lombaert, and A Y Jeng
January 1998, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!